Company Announcements

Directorate Change

Source: RNS
RNS Number : 8214U
Cambridge Cognition Holdings PLC
03 August 2022
 

3 August 2022

Cambridge Cognition Holdings Plc

 

("Cambridge Cognition", the "Company" or the "Group")

 

Directorate Change

 

Cambridge Cognition Holdings Plc (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce that further to the announcement of 6 April 2022, Stephen Symonds, Chief Financial Officer, has been appointed to the Board of Cambridge Cognition as an Executive Director with immediate effect.

 

Stephen was previously the CFO of Envigo, a provider of pre-clinical services to the pharmaceutical industry, where he spent eight years.  Prior to that, Stephen spent a decade with KPMG, working on a wide-ranging portfolio of clients.  

 

Steven Powell, Chairman of the Company, commented: "We are delighted that Stephen is joining the Board. He has extensive relevant experience and has fitted in very well with the team since joining the Company in April this year."

 

Additional Information in respect of the AIM Rules

 

The following information regarding the appointment of Stephen Daniel Symonds, aged 47, is disclosed under Schedule Two paragraph (g) of the AIM Rules for Companies:

 

Current Directorships

Previous Directorships (within the last five years)


Centralabs Clinical Research Limited


Covance Consulting Limited


Covance CRS Analytics Limited


Covance CRS Developments Limited


Covance CRS International Limited


Covance Pharma Consulting Limited


Envigo CRS (Switzerland) Limited


Envigo CRS GmbH


Envigo CRS Israel Limited


Envigo CRS SA


Envigo CRS Switzerland Limited


Envigo Holdings Limited


Envigo Monitoring Limited


Envigo RMS (UK) Limited


Envigo RMS BV


Envigo RMS GmbH


Envigo RMS India Private Limited


Envigo RMS Israel Limited


Envigo RMS Sarl


Envigo RMS SL


Envigo RMS Srl


Envigo Ventures Limited


Harlan Eurasia Holdings Limited


Harlan Europe Holdings Limited


HIH Limited


Huntingdon Consulting Engineers Limited


Huntingdon Research Centre Limited


Labcorp Research Limited


Labcorp UK Limited


Paragon Global Services Limited


Pathfinder Clinical Development Limited


Pathfinder Nominees Limited


Servicepharm Limited

 

As at the date of this announcement, Stephen Symonds holds 22,950 ordinary shares in the Company representing 0.07% of the Company's issued share capital. In addition, Stephen holds an interest in 152,671 options over ordinary shares of the Company.

 

Save as set out above there are no further disclosures pursuant to Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies in respect of the appointment of Stephen Symonds.

 

For further information, please contact:

 

Cambridge Cognition Holdings Plc

Tel: 01223 810 700

Matthew Stork, Chief Executive Officer

press@camcog.com

Stephen Symonds, Chief Financial Officer




Panmure Gordon (UK) Ltd

(NOMAD and Joint Broker)

 

Tel: 020 78862500

Freddy Crossley / Emma Earl / Mark Rodgers

(Corporate Advisory)

Rupert Dearden

(Corporate Broking)



Dowgate Capital Limited (Joint Broker)

Tel: 020 3903 7715

David Poutney / James Serjeant




IFC Advisory Ltd (Financial PR and IR)

Tel: 020 3934 6630

Tim Metcalfe / Graham Herring / Zach Cohen

cog@investor-focus.co.uk

 

Notes to Editors

 

About Cambridge Cognition

 

Cambridge Cognition is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.

 

For further information visit www.cambridgecognition.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAKZGGRFFMGZZM